Home » Topics » Immuno-oncology, BioWorld Science

Immuno-oncology, BioWorld Science
RSS

First anticancer monoclonal antibody approved by FDA

Nov. 27, 1997

Results from Leuvectin trial in kidney cancer patients reported

Nov. 26, 1997

Phase I trial of multiple-dose IDEC-C2B8 in NHL

Nov. 24, 1997

International phase III trial of Maxamine in malignant melanoma

Nov. 18, 1997

Evidence that Theratope elicits an antitumor cellular immune response presented

Nov. 18, 1997

FDA approves Intron A for non-Hodgkin's lymphoma

Nov. 12, 1997

AntiVirals to acquire ImmunoTherapy and its late-stage cancer vaccine

Nov. 7, 1997

Phase I trials begin on TNT in glioma patients

Nov. 6, 1997

Novopharm Biotech cleared for phase I trials of melanoma immunotherapy

Oct. 30, 1997

Antitumor activity of LC-9018 correlated with cytokine production

Oct. 28, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 5, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Axsome’s Auvelity cleared for large Alzheimer’s agitation market
BioWorld
Axsome Therapeutics Inc. won U.S. FDA approval for Auvelity (AXS-05) to treat Alzheimer’s disease agitation, a condition that affects up to three-quarters of...
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...